Yield10 Bioscience Statistics
Total Valuation
Yield10 Bioscience has a market cap or net worth of 499,342. The enterprise value is 2.53 million.
Market Cap | 499,342 |
Enterprise Value | 2.53M |
Important Dates
The next estimated earnings date is Tuesday, November 12, 2024.
Earnings Date | Nov 12, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
Yield10 Bioscience has 665,789 shares outstanding. The number of shares has increased by 137.43% in one year.
Shares Outstanding | 665,789 |
Shares Change (YoY) | +137.43% |
Shares Change (QoQ) | +23.90% |
Owned by Insiders (%) | 18.94% |
Owned by Institutions (%) | 0.21% |
Float | 539,657 |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 0.51 |
PB Ratio | n/a |
P/FCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | -0.20 |
EV / Sales | 3.37 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | -0.43 |
Financial Position
The company has a current ratio of 0.16
Current Ratio | 0.16 |
Quick Ratio | 0.10 |
Debt / Equity | n/a |
Debt / EBITDA | n/a |
Debt / FCF | -0.47 |
Interest Coverage | -331.39 |
Financial Efficiency
Return on Equity (ROE) | n/a |
Return on Assets (ROA) | -178.11% |
Return on Capital (ROIC) | -2,867.26% |
Revenue Per Employee | 25,862 |
Profits Per Employee | -438,000 |
Employee Count | 29 |
Asset Turnover | 0.17 |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -90.53% in the last 52 weeks.
Beta (5Y) | n/a |
52-Week Price Change | -90.53% |
50-Day Moving Average | 1.08 |
200-Day Moving Average | 3.55 |
Relative Strength Index (RSI) | 42.52 |
Average Volume (20 Days) | 5,638 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | 0.02 |
Income Statement
In the last 12 months, Yield10 Bioscience had revenue of 750,000 and -12.70 million in losses. Loss per share was -24.93.
Revenue | 750,000 |
Gross Profit | -6.46M |
Operating Income | -12.59M |
Pretax Income | -12.70M |
Net Income | -12.70M |
EBITDA | -12.32M |
EBIT | -12.59M |
Loss Per Share | -24.93 |
Balance Sheet
The company has 733,000 in cash and 2.76 million in debt, giving a net cash position of -2.03 million or -3.04 per share.
Cash & Cash Equivalents | 733,000 |
Total Debt | 2.76M |
Net Cash | -2.03M |
Net Cash Per Share | -3.04 |
Equity (Book Value) | -6.24M |
Book Value Per Share | -9.71 |
Working Capital | -6.47M |
Cash Flow
In the last 12 months, operating cash flow was -5.80 million and capital expenditures -19,000, giving a free cash flow of -5.82 million.
Operating Cash Flow | -5.80M |
Capital Expenditures | -19,000 |
Free Cash Flow | -5.82M |
FCF Per Share | -8.74 |
Margins
Gross Margin | n/a |
Operating Margin | -1,679.07% |
Pretax Margin | -1,693.60% |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | -775.73% |
Dividends & Yields
Yield10 Bioscience does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -137.43% |
Shareholder Yield | -137.43% |
Earnings Yield | -3,323.80% |
FCF Yield | -1,165.13% |
Stock Splits
The last stock split was on May 3, 2024. It was a reverse split with a ratio of 0.0416667.
Last Split Date | May 3, 2024 |
Split Type | Reverse |
Split Ratio | 0.0416667 |
Scores
Yield10 Bioscience has an Altman Z-Score of -214.14. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | -214.14 |
Piotroski F-Score | n/a |